Schering-Plough has triggered its pre-existing option to extend the current collaboration with MorphoSys for another year.
Schering-Plough will have continued access to MorphoSys’s proprietary antibody HuCAL GOLD, and contains options for therapeutic licenses.
For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to get license fees and milestone payments relating to the successful advancement of projects in clinical development, and royalties on HuCAL antibodies developed under the agreement.
Under the extended agreement, MorphoSys continues to receive annual user fees for access to its HuCAL platform.
Simon Moroney, CEO of MorphoSys, said: We are pleased with Schering-Plough’s decision to extend the current collaboration.